Transplant May Be Reasonable for Certain CRC Patients With Liver Mets
For a select group of patients with colorectal cancer and unresectable liver metastases, liver transplant may be a reasonable option, according to results from a prospective, nonrandomized controlled cohort study. Overall, among 61 patients who underwent liver transplant, the median disease-free survival (DFS) was 11.8 months (95% CI 9.3-14.2), with a 5-year DFS rate of […]
Trial Suggests Optimal Approach to Unresectable CRC Liver Mets
For patients with initially unresectable colorectal cancer liver metastases, FOLFOXIRI plus bevacizumab (Avastin) was the “preferred” systemic induction regimen for those with a right-sided or RAS- or BRAF V600E-mutated primary tumor, according to a phase III randomized trial. Among these patients, the median progression-free survival (PFS) was 9.0 months in those receiving FOLFOX or FOLFIRI […]